A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study of Recombinant Anti-human IL-17A/F Humanized Monoclonal Antibody Injection in the Treatment of Moderate-to-Severe Active Ankylosing Spondylitis (AS)
Latest Information Update: 03 Apr 2026
At a glance
- Drugs LZM 012 (Primary)
- Indications Ankylosing spondylitis
- Focus Registrational; Therapeutic Use
- Sponsors Kanova Biopharmaceutical
Most Recent Events
- 03 Apr 2026 New trial record